» Articles » PMID: 33871905

SvReg: Structural Varying-coefficient Regression to Differentiate How Regional Brain Atrophy Affects Motor Impairment for Huntington Disease Severity Groups

Overview
Journal Biom J
Specialty Public Health
Date 2021 Apr 19
PMID 33871905
Authors
Affiliations
Soon will be listed here.
Abstract

For Huntington disease, identification of brain regions related to motor impairment can be useful for developing interventions to alleviate the motor symptom, the major symptom of the disease. However, the effects from the brain regions to motor impairment may vary for different groups of patients. Hence, our interest is not only to identify the brain regions but also to understand how their effects on motor impairment differ by patient groups. This can be cast as a model selection problem for a varying-coefficient regression. However, this is challenging when there is a pre-specified group structure among variables. We propose a novel variable selection method for a varying-coefficient regression with such structured variables and provide a publicly available R package svreg for implementation of our method. Our method is empirically shown to select relevant variables consistently. Also, our method screens irrelevant variables better than existing methods. Hence, our method leads to a model with higher sensitivity, lower false discovery rate and higher prediction accuracy than the existing methods. Finally, we found that the effects from the brain regions to motor impairment differ by disease severity of the patients. To the best of our knowledge, our study is the first to identify such interaction effects between the disease severity and brain regions, which indicates the need for customized intervention by disease severity.

References
1.
Hallac D, Leskovec J, Boyd S . Network Lasso: Clustering and Optimization in Large Graphs. KDD. 2016; 2015:387-396. PMC: 4937836. DOI: 10.1145/2783258.2783313. View

2.
Garcia T, Muller S . COX REGRESSION WITH EXCLUSION FREQUENCY-BASED WEIGHTS TO IDENTIFY NEUROIMAGING MARKERS RELEVANT TO HUNTINGTON'S DISEASE ONSET. Ann Appl Stat. 2022; 10(4):2130-2156. PMC: 8896655. DOI: 10.1214/16-aoas967. View

3.
Paulsen J, Long J, Johnson H, Aylward E, Ross C, Williams J . Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study. Front Aging Neurosci. 2014; 6:78. PMC: 4000999. DOI: 10.3389/fnagi.2014.00078. View

4.
Biglan K, Ross C, Langbehn D, Aylward E, Stout J, Queller S . Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord. 2009; 24(12):1763-72. PMC: 3048804. DOI: 10.1002/mds.22601. View

5.
Paulsen J, Long J, Ross C, Harrington D, Erwin C, Williams J . Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. Lancet Neurol. 2014; 13(12):1193-201. PMC: 4373455. DOI: 10.1016/S1474-4422(14)70238-8. View